Today

Agents

Chat

Arena

Discover

More

App

AIM ImmunoTech CEO Thomas K. Equels acquires $4,862 common shares - AIM News | Rallies

AIM ImmunoTech CEO Thomas K. Equels acquires $4,862 common shares

AIM•2026-09-16

CEO buys 22,000 common shares

Thomas K. Equels, CEO and President, bought 22,000 AIM ImmunoTech common shares at $0.22 each.
Directly held stake rose to 91,822 shares following the purchase.

Related News

BofA: We Raise Our 4Q26 TTF Gas Price Forecast to 100 €/MWh

XLE•2026-09-16

Nasdaq trade halt continues <SVA.O> reason not available at 09:37 AM

SVA•2026-09-16

Novo partners with Anthropic to speed up drug development with Claude

NVO•2026-09-16

Sources

S

AIM ImmunoTech CEO Thomas K. Equels acquires $4,862 common shares

Sec

P

PetVivo Animal Health releases 2026-2027 veterinary conference and exhibition schedule

PETV•2026-09-16

Texas Capital ETFs TXS, OILT shift primary listings to Texas Stock Exchange from NYSE Arca

TXS•2026-09-16